Robeco Institutional Asset Management B.V. Has $69.76 Million Position in United Therapeutics Corporation (NASDAQ:UTHR)

Robeco Institutional Asset Management B.V. raised its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 17.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 226,287 shares of the biotechnology company's stock after purchasing an additional 34,362 shares during the period. Robeco Institutional Asset Management B.V. owned 0.50% of United Therapeutics worth $69,757,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Wealthfront Advisers LLC grew its stake in United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after buying an additional 18,313,424 shares during the last quarter. Vanguard Group Inc. boosted its holdings in United Therapeutics by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock valued at $1,567,253,000 after acquiring an additional 32,213 shares during the period. FMR LLC grew its position in shares of United Therapeutics by 36.5% in the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after purchasing an additional 393,777 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of United Therapeutics by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock worth $401,184,000 after purchasing an additional 44,277 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of United Therapeutics by 0.8% during the 4th quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock worth $344,176,000 after purchasing an additional 7,710 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. UBS Group lowered their target price on United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a report on Monday. Bank of America lowered their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. HC Wainwright reissued a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Finally, Morgan Stanley raised their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $386.15.

United Therapeutics Stock Up 1.1%

UTHR traded up $3.08 during midday trading on Monday, reaching $287.35. 397,145 shares of the company's stock were exchanged, compared to its average volume of 445,911. The business has a 50-day simple moving average of $301.19 and a two-hundred day simple moving average of $324.08. The firm has a market capitalization of $12.96 billion, a price-to-earnings ratio of 11.47, a price-to-earnings-growth ratio of 6.22 and a beta of 0.57. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. United Therapeutics's quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.17 EPS. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director directly owned 19,384 shares in the company, valued at $5,613,606.40. The trade was a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the sale, the executive vice president directly owned 36,781 shares in the company, valued at $10,297,208.76. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 91,681 shares of company stock valued at $27,319,919. 10.30% of the stock is owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.